Morningstar Investor users sign in here.

Stocks

Capital issues deliver solid performances

Investors have mostly made attractive returns by participating in these COVID-19 raisings, with a median return of 14 per cent for capital issues. 

Mentioned: Cochlear Ltd (COH), Flight Centre Travel Group Ltd (FLT), Metcash Ltd (MTS), National Australia Bank Ltd (NAB), oOh media Ltd (OML), QBE Insurance Group Ltd (QBE), Qube Holdings Ltd (QUB), Ramsay Health Care Ltd (RHC), Webjet Ltd (WEB)


Recent capital raisings have paid off for participating shareholders, with those priced at bigger discounts such as Flight Centre’s entitlement offer delivering immediate returns and surprising investors.

According to data from consulting firm Vesparum, $20 billion of capital raisings were announced between 1 April and 15 May. The surge in capital raisings came as market volatility levels subsided and the ASX temporarily relaxed capital raising rules in response to the coronavirus pandemic.

Most of these capital issues have been offered to existing retail shareholders at discounts to their market prices in the form of share purchase plans  or entitlement offers to buy additional shares in proportion to existing holdings.

Investors have mostly made attractive returns by participating in these COVID-19 raisings, with a median return of 14 per cent for capital issues and 58 per cent for offers priced at a 30 per cent-plus discount to a company’s market price.

“On an annualised basis, these returns are extraordinary,” Vesparum said in a research paper on the topic, Analysis of capital raisings in the COVID-19 period.

Immediate gains pocketed

Drew Meredith, director and adviser at Wattle Partners, says there have been some surprisingly good results, especially for companies struggling the most with the coronavirus pandemic.

“Interestingly, it has been those businesses that were relying on a successful capital raising just to survive that have recovered most strongly. Webjet (ASX: WBJ) and Ooh! Media (ASX: OML) are both up over 100 per cent and Flight Centre (ASX: FLT) is around 49 per cent [as at May 22],” said Meredith.

“The big question, however, is: will these companies require another round of capital before 2020 is out? With the threat of JobKeeper being pulled, spiking inflation and continued border closures, it’s difficult to see the travel industry recovering anytime soon,” says Meredith.

The biggest capital raising to date has been from National Australia Bank (ASX: NAB). NAB’s SPP offer price of $14.15 represented a substantial discount to Morningstar’s fair value of $25.00, so Morningstar bank analyst Nathan Zaia had recommended investors participate.

“We do believe the bank is materially undervalued, with the market overly focused on near-term earnings,” he said. At 2.50pm on Monday, NAB shares were trading at $15.68.

Shareholders who bought into the SPP of hearing implant maker Cochlear (ASX: COH) would be happy, for now. The shares were sold to existing shareholders at a price of $140 and have traded above $180 since the offer closed in April, giving shareholders a gain of at least 20 per cent.

But getting hold of the shares was difficult and the offer was well oversubscribed, reflecting the popularity of healthcare stocks.

Morningstar analyst Nicolette Quinn says Cochlear’s SPP has the effect of reducing Morningstar’s five-year EPS forecast compound annual growth rate to 5.4 per cent from 5.8 per cent prior.

However, because the SPP was priced near Morningstar’s $139 fair value estimate, the increased equity raising has minimal impact on its valuation. But at current levels close to $190 a share, Cochlear shares screen as overvalued.

Man wearing cochlear implant

Shareholders who bought into the SPP of hearing implant maker Cochlear would be happy, for now.

Need to look past short-term

In each capital raisings Meredith has tracked, shareholders have been better off, at least in the short term, “except for long-suffering Metcash (ASX: MTS) and QBE (ASX: QBE) investors.”

“Some of the higher quality raisings in our view have been Qube Holdings (ASX: QUB) and Ramsay Healthcare (ASX: RHC). Both companies suggested the proceeds would be used for further acquisitions and organic growth, delivering a return of 35 per cent and 21 per cent each to date [to May 22],” says Meredith.

In contrast, QBE offered shares at a price of $8.25 to existing shareholders, well below its recently revised fair value of $11. The insurer’s shares have traded below $8 since the offer closed, so shareholders who bought in have borne an initial loss. 

But according to Meredith, any good or bad returns reflect only a very short period of time and don’t consider the capital lost prior to their announcement. “I’d suggest the companies not [issuing capital] are where investors should really be looking.”

Morningstar’s Zaia says shareholders should not judge the success of participating in a capital raising by where the share price is trading weeks or months later.  

“We cannot, and do not, try and predict where share prices will go short-term,” he says. “Sometimes better opportunities to purchase on market following a raising do present.”

Nor should shareholders participate in an equity raising hoping to make a quick buck.

Instead, think about your portfolio and how any additional shares would fit.

“Consider what value you ascribe the company long-term, and whether more exposure to the company and sector makes sense for your portfolio,” Zaia says.

Prem Icon

 



© 2023 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This report has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or New Zealand wholesale clients of Morningstar Research Ltd, subsidiaries of Morningstar, Inc. Any general advice has been provided without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide at www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782.

More from Morningstar

Why Berkshire Hathaway’s success will continue after Charlie Munger ... and Warren Buffett
Stocks

Why Berkshire Hathaway’s success will continue after Charlie Munger ... and Warren Buffett

Munger’s passing is a spiritual loss for the company.
Morningstar initiates coverage on 3 new shares
Stocks

Morningstar initiates coverage on 3 new shares

There are 2 undervalued names as part of our new coverage. 
3 shares for income investors
Stocks

3 shares for income investors

A dividend screen is a jumping off point for further research.
What we think of Morningstar subscribers' most traded share
Stocks

What we think of Morningstar subscribers' most traded share

This stock was the second largest ‘buy’ for 2023 and was also the second largest ‘sell’ for Morningstar subscribers.
How to build an income portfolio
Stocks

How to build an income portfolio

Investors love dividends but creating an income stream involves more than just picking the highest yielding shares.
The art of buying stocks at 52-week lows
Stocks

The art of buying stocks at 52-week lows

Stock markets are highly efficient in the long run yet share prices can fluctuate wildly near term. The art of investing is buying quality stocks...